Gepants for headache prevention in children and adolescents: A multicenter chart review study.
Lauren Shin, Olivia Mentz, Amy A Gelfand...
https://pubmed.ncbi.nlm.nih.gov/41235617/Actively Recruiting
Led by AbbVie · Updated on 2026-10-06
450
Participants Needed
98
Research Sites
8 weeks
Total Duration
This research aims to evaluate the safety and effectiveness of atogepant, a medication currently approved for adults, in treating episodic migraine in children aged 6 to 17 years. The study focuses on pediatric participants who experience moderate to severe migraines with symptoms such as throbbing head pain, nausea, and sensitivity to light and sound. Limited treatment options exist for this age group, so the trial investigates different doses of atogepant to address this need. Participants are divided into groups based on age and receive either a placebo or low or high doses of atogepant tablets once daily for 12 weeks. Children aged 6 to 11 first undergo an open-label pharmacokinetic substudy to determine the appropriate dose before the double-blind treatment period. After the initial 12 weeks, participants either have a follow-up visit 4 weeks after their last dose or can continue receiving atogepant for an additional 52 weeks in an extension study. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor the effects of treatment and check for side effects. The main outcomes measured include changes in monthly migraine days and safety through adverse event tracking. The study plans to enroll about 450 children worldwide, with comprehensive monitoring over the treatment and follow-up periods.
CONDITIONS
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
A
ABBVIE CALL CENTER
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AbbVie
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Atogepant | Placebo | Current Preventive Care |
|---|---|---|---|
| What it is | A study drug being evaluated for preventing episodic migraine in children and adolescents | An inactive matching oral tablet used as a control | Common preventive drugs such as topiramate or beta blockers are used off‑label to reduce migraine frequency in children |
| Role in trial | Participants receive the experimental oral therapy | Participants receive a placebo oral tablet | Represents what medicines are typically offered outside of trials |
| Primary use | Preventive treatment to reduce migraine frequency in pediatric patients | Control to measure trial drug effects against no active treatment | Used to decrease migraine attacks in children based on clinical experience and some evidence |
| How it is given | Oral tablets given during study according to protocol | Oral placebo tablets given in matching fashion | Oral medications such as topiramate or beta blockers prescribed by clinicians outside this study |
| Evidence status | Efficacy and safety are being evaluated in this pediatric trial; results are not yet established | Used as control; no clinical benefit expected | Some evidence supports reduced migraine frequency with agents like topiramate, though overall pediatric data remain limited |
| Important risks | Risks are being monitored in the trial and are not yet characterized | Placebo has no pharmacologic risk, but trial adverse events will still be tracked | Medications like topiramate can have side effects such as weight change or cognitive effects, and risks vary by drug |
| Important limitations | Results may not apply beyond ages 6‑17 or beyond episodic migraine population | As placebo, it offers no preventive benefit; only serves as control | Clinical use data derive from off‑label use and data in children are limited |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Regular visits at hospital or clinic for assessments
Duration - Up to 12 weeks
Participants aged 6 to 11 receive atogepant Dose A or Dose B tablets to determine the appropriate dose for this age group.
Regular visits for dosing and monitoring
Duration - 12 weeks
Participants aged 6 to 17 are randomly assigned to receive placebo, low-dose, or high-dose atogepant tablets once daily for 12 weeks.
Regular visits for medication administration and assessments
Duration - 4 to 52 weeks
After treatment, participants either have a follow-up visit 4 weeks after last dose or continue in an extension study with atogepant for up to 52 weeks.
Follow-up visit or ongoing visits during extension
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
8
Have more questions? Get in touch with our team for quick support
Lauren Shin, Olivia Mentz, Amy A Gelfand...
https://pubmed.ncbi.nlm.nih.gov/41235617/AbbVie
Lead Sponsor